ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.593,70
0,17%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Invivyd Inc (IVVD)

  7. Invivyd Inc (IVVD) News

IVVD

Invivyd (IVVD)

Invivyd Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IVVD
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202413h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
31/05/202413h05GlobeNewswire Inc.Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for SerialNASDAQ:IVVDInvivyd Inc
31/05/202413h00GlobeNewswire Inc.Invivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerNASDAQ:IVVDInvivyd Inc
29/05/202413h00GlobeNewswire Inc.Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)NASDAQ:IVVDInvivyd Inc
24/05/202400h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
24/05/202400h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
23/05/202423h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
23/05/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
23/05/202422h50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc
22/05/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
22/05/202413h00GlobeNewswire Inc.Invivyd Elects Two New Independent Members to its Board of DirectorsNASDAQ:IVVDInvivyd Inc
16/05/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IVVDInvivyd Inc
13/05/202422h01GlobeNewswire Inc.Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:IVVDInvivyd Inc
09/05/202422h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IVVDInvivyd Inc
09/05/202422h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
09/05/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
09/05/202422h01GlobeNewswire Inc.Invivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
07/05/202413h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
07/05/202413h30GlobeNewswire Inc.Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackNASDAQ:IVVDInvivyd Inc
02/05/202423h13GlobeNewswire Inc.Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsNASDAQ:IVVDInvivyd Inc
30/04/202413h30GlobeNewswire Inc.Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionNASDAQ:IVVDInvivyd Inc
15/04/202413h30GlobeNewswire Inc.Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™NASDAQ:IVVDInvivyd Inc
12/04/202413h30GlobeNewswire Inc.Invivyd Announces CEO TransitionNASDAQ:IVVDInvivyd Inc
04/04/202422h01GlobeNewswire Inc.Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionNASDAQ:IVVDInvivyd Inc
28/03/202412h00GlobeNewswire Inc.Invivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
22/03/202420h28GlobeNewswire Inc.Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialNASDAQ:IVVDInvivyd Inc
22/03/202420h04GlobeNewswire Inc.Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19NASDAQ:IVVDInvivyd Inc
12/02/202422h01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IVVDInvivyd Inc
09/02/202422h47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IVVDInvivyd Inc
09/02/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
 Showing the most relevant articles for your search:NASDAQ:IVVD

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
FX
EURJPY
Euro vs Yen
TG
LHA
Deutsche Lufthansa
NYSE
NKE
Nike
FX
EURGBP
Euro vs Sterling
USOTC
ADDYY
Adidas (QX)
TG
NOV
Novo Nordisk
CCOM
US500
US 500
TG
MBG
MercedesBenz
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
TG
ALV
Allianz
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten